Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease

키워드

참고문헌 (77)

1. Nakase H, "How to select and use IBD drugs" (2015), Yodosha Co., Ltd.
2. Nakase H, "To master the optimal therapy for ulcerative colitis" (2018), Igakutokangosha Co., Ltd
3. Stolfi C, "Mechanisms of action of non-steroidal anti-inflammatory drugs(NSAIDs)and mesalazine in the chemoprevention of colorectal cancer", Int J Mol Sci, 14, pp.17972~17985 (2013)
4. Oh-Oka K, "Induction of colonic regulatory T cells by mesalamine by activating the aryl hydrocarbon receptor", Cell Mol Gastroenterol Hepatol, 4, pp.135~151 (2017)
5. Marshall JK, "Rectal aminosalicylate therapy for distal ulcerative colitis : a meta-analysis", Aliment Pharmacol Ther, 9, pp.293~300 (1995)
6. Hiroshi Nakase, "Treatment of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2nd Asian Organization of Crohn’s and Colitis (AOCC) meeting in Seoul", Intestinal research, 14(3), pp.231~239 (2016), 대한장연구학회
7. Sutherland L, "Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis", Cochrane Database Syst Rev, (2), pp.CD000543~ (2006)
8. Haruhiko Ogata, "Comparison of efficacy of multimatrix mesalazine 4.8 g", day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study, 2017, pp.15(3), 368~379[DOI]
9. Sutherland L, "Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis", Cochrane Database Syst Rev, (2), pp.CD000544~ (2006)
10. Flourié B, "Randomised clinical trial : once-vs. twice-daily prolonged-release mesalazine for active ulcerative colitis", Aliment Pharmacol Ther, 37, pp.767~775 (2013)
11. Kruis W, "Randomised clinical trial : a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis", Aliment Pharmacol Ther, 33, pp.313~322 (2011)
12. Lichtenstein GR, "Practice Parameters Committee of American College of Gastroenterology. Management of Crohn’s disease in adults", Am J Gastroenterol, 104, pp.465~483 (2009)
13. Coward S, "Comparative effectiveness of mesalamine, sulfasalazine, corticosteroids, and budesonide for the induction of remission in Crohn’s disease : a Bayesian network meta-analysis", Inflamm Bowel Dis, 23, pp.461~472 (2017)
14. Mowat C, "Guidelines for the management of inflammatory bowel disease in adults", Gut, 60, pp.571~607 (2011)
15. Nenci A, "Epithelial NEMO links innate immunity to chronic intestinal inflammation", Nature, 446, pp.557~561 (2007)
16. Inoue S, "The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease", Clin Exp Immunol, 156, pp.172~182 (2009)
17. Creed TJ, "Review article : steroid resistance in inflammatory bowel disease-mechanisms and therapeutic strategies", Aliment Pharmacol Ther, 25, pp.111~122 (2007)
18. Ford AC, "Glucocorticosteroid therapy in inflammatory bowel disease : systematic review and meta-analysis", Am J Gastroenterol, 106, pp.590~599 (2011)
19. Hart AL, "Review article : the optimal medical management of acute severe ulcerative colitis", Aliment Pharmacol Ther, 32, pp.615~627 (2010)
20. Baron JH, "Out-patient treatment of ulcerative colitis : comparison between three doses of oral prednisone", Br Med J, 2, pp.441~443 (1962)
21. Dignass A, "The second European evidence-based consensus on the diagnosis and management of Crohn’s disease : current management", J Crohns Colitis, 4, pp.28~62 (2010)
22. Lichtenstein GR, "American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease", Gastroenterology, 130, pp.940~987 (2006)
23. Turner D, "Response to corticosteroids in severe ulcerative colitis : a systematic review of the literature and a meta-regression", Clin Gastroenterol Hepatol, 5, pp.103~110 (2007)
24. Shin JY, "Thiopurine prodrugs mediate immunosuppressive effects by interfering with Rac1 protein function", J Biol Chem, 291, pp.13699~13714 (2016)
25. Gisbert JP, "Meta-analysis : the efficacy of azathioprine and mercaptopurine in ulcerative colitis", Aliment Pharmacol Ther, 30, pp.126~137 (2009)
26. Satoshi Yamada, "Efficacy and Safety of Long-Term Thiopurine Maintenance Treatment in Japanese Patients With Ulcerative Colitis", Intestinal research, 13(3), pp.250~258 (2015), 대한장연구학회
27. Pearson DC, "Azathioprine for maintaining remission of Crohn’s disease", Cochrane Database Syst Rev, (2), pp.CD000067~ (2000)
28. 이강문, "Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID)", Intestinal research, 13(3), pp.193~207 (2015), 대한장연구학회
29. Pinto AL, "Azathioprine therapy in steroid-dependent patients with Crohn disease : results of a 10-year longitudinal follow-up study", Med Sci Monit, 15, pp.PI19~PI26 (2009)
30. Chebli LA, "Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis", Inflamm Bowel Dis, 16, pp.613~619 (2010)
31. Takagi Y, "Human MTH3(NUDT18)protein hydrolyzes oxidized forms of guanosine and deoxyguanosine diphosphates : comparison with MTH1 and MTH2", J Biol Chem, 287, pp.21541~21549 (2012)
32. Carter M, "Crystal structure, biochemical and cellular activities demonstrate separate functions of MTH1 and MTH2", Nat Commun, 6, pp.7871~ (2015)
33. Valerie NC, "NUDT15 hydrolyzes 6-Thio-DeoxyGTP to mediate the anticancer efficacy of 6-thioguanine", Cancer Res, 76, pp.5501~5511 (2016)
34. Moriyama T, "NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity", Nat Genet, 48, pp.367~373 (2016)
35. Yang SK, "A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia", Nat Genet, 46, pp.1017~1020 (2014)
36. Kakuta Y, "NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD", Pharmacogenomics J, 16, pp.280~285 (2016)
37. Yoshino T, "Efficacy and safety of granulocyte and monocyte adsorption apheresis for ulcerative colitis : a meta-analysis", Dig Liver Dis, 46, pp.219~226 (2014)
38. Yoshimura N, "An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active Crohn’s disease", BMC Gastroenterol, 15, pp.163~ (2015)
39. Fukuchi T, "Therapeutic effect of intensive granulocyte and monocyte adsorption apheresis combined with thiopurines for steroid-and biologics-naïve Japanese patients with early-diagnosed Crohn’s disease", BMC Gastroenterol, 13, pp.124~ (2014)
40. Naganuma M, "The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease", J Gastroenterol, 46, pp.129~137 (2011)
41. Lichtiger S, "Treatment of choice for acute severe steroid-refractory ulcerative colitis is cyclosporine", Inflamm Bowel Dis, 15, pp.141~142 (2009)
42. Lichtiger S, "Cyclosporine in severe ulcerative colitis refractory to steroid therapy", N Engl J Med, 330, pp.1841~1845 (1994)
43. Van Assche G, "Randomized, double-blind comparison of 4 mg", kg versus 2 mg, Gastroenterology, pp.2003, 125[DOI]
44. Stange EF, "European trial of cyclosporine in chronic active Crohn’s disease : a 12-month study. The European Study Group", Gastroenterology, 109, pp.774~782 (1995)
45. Brynskov J, "A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn’s disease", N Engl J Med, 321, pp.845~850 (1989)
46. Rusnak F, "Calcineurin : form and function", Physiol Rev, 80, pp.1483~1521 (2000)
47. Wong SH, "Therapeutic drug monitoring for immunosuppressants", Clin Chim Acta, 313, pp.241~253 (2001)
48. Yoshino T, "Immunosuppressive effects of tacrolimus on macrophages ameliorate experimental colitis", Inflamm Bowel Dis, 16, pp.2022~2033 (2010)
49. Kino T, "FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro", J Antibiot(Tokyo), 40, pp.1256~1265 (1987)
50. Ogata H, "A randomised dose finding study of oral tacrolimus(FK506)therapy in refractory ulcerative colitis", Gut, 55, pp.1255~1262 (2006)
51. Baumgart DC, "Tacrolimus(FK506)for induction of remission in refractory ulcerative colitis", Cochrane Database Syst Rev, (3), pp.CD007216~ (2008)
52. Yamamoto S, "Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis", Aliment Pharmacol Ther, 28, pp.589~597 (2008)
53. Fellermann K, "Response of refractory colitis to intravenous or oral tacrolimus(FK506)", Inflamm Bowel Dis, 8, pp.317~324 (2002)
54. Högenauer C, "Effect of oral tacrolimus(FK 506)on steroid-refractory moderate", severe ulcerative colitis, 2003, pp.18, 415~423
55. Baumgart DC, "Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease : a long-term follow-up", Am J Gastroenterol, 101, pp.1048~1056 (2006)
56. Schmidt KJ, "Long-term outcomes in steroid-refractory ulcerative colitis treated with tacrolimus alone or in combination with purine analogues", J Crohns Colitis, 10, pp.31~37 (2016)
57. Niederreiter L, "Anti-IL-12", 23 in Crohn’s disease : bench and bedside, 2013, pp.14, 1379~1384
58. McSharry K, "Systematic review : the role of tacrolimus in the management of Crohn’s disease", Aliment Pharmacol Ther, 34, pp.1282~1294 (2011)
59. Gerich ME, "Tacrolimus salvage in anti-tumor necrosis factor antibody treatment-refractory Crohn’s disease", Inflamm Bowel Dis, 19, pp.1107~1111 (2013)
60. D’Haens G, "Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease : an open randomized trial", Lancet, 371, pp.660~667 (2008)
61. Khanna R, "Early combined immunosuppression for the management of Crohn’s disease(REACT) : a cluster randomised controlled trial", Lancet, 386, pp.1825~1834 (2015)
62. Present DH, "Infliximab for the treatment of fistulas in patients with Crohn’s disease", N Engl J Med, 340, pp.1398~1405 (1999)
63. Colombel JF, "Infliximab, azathioprine, or combination therapy for Crohn’s disease", N Engl J Med, 362, pp.1383~1395 (2010)
64. Hanauer SB, "Human anti-tumor necrosis factor monoclonal antibody(adalimumab)in Crohn’s disease : the CLASSIC-I trial", Gastroenterology, 130, pp.323~333 (2006)
65. Rutgeerts P, "Infliximab for induction and maintenance therapy for ulcerative colitis", N Engl J Med, 353, pp.2462~2476 (2005)
66. Sandborn WJ, "Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab", Gastroenterology, 137, pp.1250~1260 (2009)
67. Limdi JK, "Golimumab for ulcerative colitis : adding perspective to the pursuit", Frontline Gastroenterol, 9, pp.232~233 (2018)
68. Neurath MF, "Cytokines in inflammatory bowel disease", Nat Rev Immunol, 14, pp.329~342 (2014)
69. Neurath MF, "IL-23 : a master regulator in Crohn disease", Nat Med, 13, pp.26~28 (2007)
70. Wang K, "Diverse genome-wide association studies associate the IL12", IL23 pathway with Crohn disease, 2009, pp.84, 399~405
71. Feagan BG, "Ustekinumab as Induction and maintenance therapy for Crohn’s disease", N Engl J Med, 375, pp.1946~1960 (2016)
72. Feagan BG, "Vedolizumab as induction and maintenance therapy for ulcerative colitis", N Engl J Med, 369, pp.699~710 (2013)
73. Soler D, "The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases", J Pharmacol Exp Ther, 330, pp.864~875 (2009)
74. Christensen B, "Safety and efficacy of combination treatment with calcineurin inhibitors and vedolizumab in patients with refractory inflammatory bowel disease", Clin Gastroenterol Hepatol, 17, pp.486~493 (2019)
75. Buer LCT, "Combining anti-TNF-alpha and vedolizumab in the treatment of inflammatory bowel disease : a case series", Inflamm Bowel Dis, 24, pp.997~1004 (2018)
76. Verstockt B, "New treatment options for inflammatory bowel diseases", J Gastroenterol, 53, pp.585~590 (2018)
77. Sandborn WJ, "Tofacitinib as induction and maintenance therapy for ulcerative colitis", N Engl J Med, 376, pp.1723~1736 (2017)

관련 논문AI추천